Bristol Myers Squibb Strengths And Weaknesses

Superior Essays
Bristol-Myers Squibb overall performance positions them as one of the world’s largest bio-pharmaceutical leader. The company business level, functional level and corporate level strategies assisted with overpowering their challenges. The qualitative research method conducted provides a generalized aspect of the company internal weakness, strengths, threats and opportunities the company encountered. The weaknesses shown occurs in the leadership and decision making due to loss of patent protection and decline in revenues. This analysis provides an action plan that would help the company strategically in maintaining a strong advantage. It gives recommendations and strategies that can be implemented within the company. In order for a company to sustain a competitive advantage there must be consistency and a continuous stream of operations. BMS is in a good financial and competitive position and is able to maintain it with the proper actions and …show more content…
The company focuses on the unmet medical needs of patients with serious diseases. Its product line includes chemically-synthesized drugs and biological products, which focus on areas like cancer, psychiatric disorders, cardiovascular disorders, diabetes, hepatitis B, HIV/AIDS and rheumatoid arthritis (GlobalData, 2014). This research analyzed the internal weakness of Bristol-Myers Squibb. The internal weakness reveal losses in patent protection, lawsuits and decline in revenues due to a lack in leadership and poor managerial decision making. Research showed that BMS patent loss for some of its major seller drugs include Plavix, Abilify and Avapro lead to a huge plunge in revenues. In 2012, Avapro revenues decline by 17 percent to $17.6 billion (Hoovers, 2015). In comparison, Abilify accounted for about $1.54 billion in revenues the first nine months in 2014 (Trefis,

Related Documents

  • Superior Essays

    Purinex Case Study

    • 1463 Words
    • 6 Pages

    “The partnership, if secured, would enable Purinex to develop one of its leading compounds into drug for the treatment of one of the world’s deadliest and most widespread diseases.” The problem is the company had only enough cash and had not sales. The CFO of Purinex, Gilad Harpaz thought that if a partnership deal survive, the Purinex might be in perfect situation to fulfill its work. “Harpaz thought that the company could either try secure financing now or wait until struck a partnership deal. The company had a lot of comprehensive technologies was under evolution, and had a suitable partnership deal one for sepsis and the second one is for diabetes.…

    • 1463 Words
    • 6 Pages
    Superior Essays
  • Decent Essays

    This is the transcript of a radio interview with Mario Szenol, an associate professor of medical oncology at Yale Cancer Centre. During the interview, Dr. Sznol talks about the process of drug development and clinical trials. He describes the drug development process as being long, saying 7 to 10 years are requiered for a successful drug to become available. The doctor summarises the implications of every phase of the process. He also states that only 10% of the drugs that enter the clinical trials in cancer will eventually get approval by the Food and Drug Administration.…

    • 253 Words
    • 2 Pages
    Decent Essays
  • Decent Essays

    Medus Valley Swot

    • 506 Words
    • 3 Pages

    The SWOT analysis is important for any company. It is necessary to run a SWOT analysis throughout the life of a company. The Main SWOT analysis will stay the same. There will be SWOT changes throughout the lifetime of the company.…

    • 506 Words
    • 3 Pages
    Decent Essays
  • Decent Essays

    Bill Jenison, president of Pharmacy Gold, said the pharmaceutical company-PBM mergers will allow his independent PBM to "leverage more enrollment because of our clinical objectivity and independence." With existing PBMs prepared to handle increased market share, and new PBMs forming, the arguments that the manufacturer-PBM mergers increase the barriers to entry into the industry, or foreclose unique products or services, are weakened. Additionally, no pharmaceutical company makes every drug on a formulary list, so the possibility of strict foreclosure is diminished because the PBMs must maintain supplier relationships with other manufacturers. A different issue arises from these continued supplier relationships concerning more subtle ways in which…

    • 6621 Words
    • 27 Pages
    Decent Essays
  • Decent Essays

    Med Tech Pharmaceuticals

    • 371 Words
    • 2 Pages

    The MedTech Pharmaceuticals Company spent three years in developing a new drug for skin cancer. Med Tech Pharmaceuticals was committed to this new medication. Nevertheless, the special government employee and advisor Baruch Fischoff for the Food and Drug Administration created government programs to help the public with their needs. This consisted of producing improved options or assisting them to select from options that already exist. The agency did not think about what the next step after accomplishing the creation of the drug and the approval of the FDA.…

    • 371 Words
    • 2 Pages
    Decent Essays
  • Superior Essays

    Moreover, BCG would provide an organization with the know-how of determining the needs and strengths of all the departments of a healthcare organization thereby enable it apply adaptive strategies. BCG provides an organization with a full picture of the positions of its business concerns thereby drawing attention to investment characteristics, cash flows and organizational business needs thus enabling the organization to sustain a balanced…

    • 1065 Words
    • 5 Pages
    Superior Essays
  • Superior Essays

    Allowing a drug company to have a monopoly where it can charge whatever it can force the individual, or more typically the insurer or the government, to pay makes little sense” (Baker). Medical pharmaceuticals are perfectly inelastic, meaning that at any price,…

    • 1507 Words
    • 7 Pages
    Superior Essays
  • Superior Essays

    Below is a chart that shows how technology and productivity have helped increase the revenue of Pharmaceutical companies in the last five years. One would notice that with the increase in technology, the revenue generated by this industry has been on the high rise. Thus allowing the companies to explore better ways of improving their products. That is to say, the table shows how the increase in money has been able to aid companies in the research and development aspect. Effects of the United States monetary policy and fiscal policy on the financial performance of Johnson and Johnson…

    • 1251 Words
    • 5 Pages
    Superior Essays
  • Improved Essays

    1960s Thalidomide Scare

    • 1072 Words
    • 5 Pages

    Public Health Problem The 1960s “Thalidomide Scare” occurred due to the negligence of pharmaceutical companies, bent on seeking profit regardless of outstanding public health concerns and the limitation of drug regulation by international governments. Thalidomide continues to negatively affect fetuses as a teratogen in underdeveloped nations, like Brazil, where drug surveillance is inadequate (Vianna et el. 2011). Additional societal stigma regarding the demonized drug hinders its availability to be researched and used in beneficial therapies for diseases including leprosy (Naafs 2006).…

    • 1072 Words
    • 5 Pages
    Improved Essays
  • Improved Essays

    The rapid growth in expenditures has resulted in pharmaceutical companies to increase prescription medication prices, however, provide poor quality medicines. “Since increasing the price of pharmaceuticals has little effect on their demand, consumers and the public bear the consequences of high prices” (Witktorowicz, 2010, p. 304). The authors examine Patented Medicine Prices Review Board (PMPRB), which protects consumers in ensuring the prices in Canada from wholesalers, hospitals, pharmacies or other, are not excessively priced. Hence, it provides a vision of pharmaceutical companies investing long-term investments for themselves. It analyzes the government's decision towards the health care system; whether or not, how health is the Canadian health-care system.…

    • 895 Words
    • 4 Pages
    Improved Essays
  • Improved Essays

    A drug named Daraprim price was raised by 5000%, from $13.50 to $750 per pill. Many cases similar to Daraprim have happened, and a pattern of massive price increase of many life saving drugs by pharmaceutical companies becomes apparent. Expensive drugs had forced patients to make difficult choices, either to cut down basic needs to save money to buy the needed drugs, or to cut down the use of the drugs itself. Americans start blaming drug companies of price gouging and call for drug prices regulation by government. Drug companies, on the other hand, blame health insurance companies for shifting the cost of purchasing drugs to patients.…

    • 1043 Words
    • 5 Pages
    Improved Essays
  • Improved Essays

    Genzyme Corporation Environmental Analysis By Dinithi Fernando S00177109 Executive Summary This report presents a decisive analysis of internal and external environments of Genzyme Corporation prior to its acquisition by Sanofi Plc. The analysis of environments is measured with the help of SWOT analysis, PESTEL analysis and Poter’s five force analysis. Moreover, this report also hit upon some problems that the company had to encounter while running the business in changing environment and recommendation as how Genzyme could sustain their independency through improving their production strategies.…

    • 981 Words
    • 4 Pages
    Improved Essays
  • Great Essays

    esentation analyses the events leading up to the 2004 merger between the pharmaceutical companies Sanofi-Synthelabo and Aventis. It reveals the social, commercial and political complexities and challenges of a merger process in which the defence of French national interests and regional capabilities competed with traditional ‘commercial’ narratives before the deal was closed. presentation critically evaluates the competing criteria adopted by government and industry to justify different merger scenarios and considers the implications for pharmaceutical innovation, industry consolidation and M&A theory The American economy greatest market for the pharmaceutical industry in 2004 the tax cuts and the lower interest rates stimulated expansion…

    • 1499 Words
    • 6 Pages
    Great Essays
  • Great Essays

    Pfizer should also reduce their cost in administrative and advertising and pump in more resources into the research and development department so that they will be able to come up with new and improved drugs. Due to the decline in blockbuster sales and new inventions within the pipeline, it would be wise to move into more personalized treatment such as cancer. Pfizer should not only rely on the "Cash Cow "products because the industry is a now facing a shift and the one size fits all approach is not valid anymore. Pfizer should consider acquiring smaller drug companies to strengthen its portfolio since their labs are not churning out enough blockbuster products.…

    • 1041 Words
    • 5 Pages
    Great Essays
  • Improved Essays

    Embed BCM Culture The BCM manager ensures that BCM program is embed to organization by executing various business continuity awareness sessions and trainings. Since the BCM program approached holistically, there are multiple BCM teams involved to execute the right tasks with great competence and skills. BCM teams are fully aware of the Business Continuity plan and are fully prepared for handling an incident or crisis by training and testing those teams periodically. The following exhibits the KPI of target vs achived.…

    • 1403 Words
    • 6 Pages
    Improved Essays